Noor H Sabariah1 
,
Maisharah SG Siti1,
Aizal CH Nor2,
Amer Hayat Khan1
For correspondence:- Noor Sabariah Email: sabariahnoor@yahoo.com Tel:+ 6097671186
Received: 8 Decemebr 2013 Accepted: 29 August 2014 Published: 19 October 2014
Citation: Sabariah NH, Siti MS, Nor AC, Khan AH. Cholestatic Hepatitis Secondary to Carbamazepine Treatment with Ursodeoxycholic Acid - A Case Report. Trop J Pharm Res 2014; 13(10):1745-1747 doi: 10.4314/tjpr.v13i10.26
© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Background: Drug-induced hepatitis and several features of liver toxicity associated with the administration of carbamazepine have been reported; they involve non-immunoallergic hepatotoxicity and immunoallergic hypersensitivity syndrome. Ursodeoxycholic acid (UDCA) has liver protective effects and is indicated for hepatitis.
Case: An 18-year old patient with epilepsy and on carbamazepine 200 mg once daily was admitted to a hospital for generalised rash and significant elevation of liver enzymes. Carbamazepine was discontinued and replaced with leviteracetam 250 mg twice daily. Patient had cholestatic features of liver damage and UDCA 500 mg twice daily was given for 2 weeks until liver enzymes normalized.
Conclusion: Ursodeoxycholic acid treatment could be an alternative treatment for patient with carbamazepine-induced hepatitis.
Archives
News Updates
Fulltext in PDF